1Rose PG.Surgery for recurrent ovarian cancer[J].Semin Oncol,2000,27(3 suppl 7):17-23.
2Cremers Q,Bolis G,Gone M,et al.Topetecan,an active drug in the second-line treatment of epithelial ovarian cancer,results of a large European phase 2 study[J].J Clin Oncol,1996,14(12):3056-3061.
3Thigpen JT,BlessingJA,Ball H,et al.Phase 1/trial of paclitaxel in patients with progressive ovarian carcinoma after platinum based chemotherapy:a Gynecologic Oncology Group study[J].J Clin Oncol,1994,12(9):1748-1753.
4Bristow RE,Tomacruz RS,Armstrong DK,et al.Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platimun era:a meta-analysis[J].J Clin Oncol,2002,20(5):1248-1259.
5Brun JL,Feyler A,Chene C,et al.Long-term results and prognostic factors in patients with epithelial ovarian cancer[J].Gynecol Oncol,2000,78 (1):21-27.
6Tay EH,Grant PT,Gebski V,et al.Secondary cytoreductive surgery for recurrent epithelial ovarian cancer[J].Obstet Gynecol,2002,99(6):1008-1013.
7Bristow RE,Lagasse LD,Karlan BY.Secondary surgery cytoreduction for advanced epithelial ovarian cancer.Patient selection and review of the literature[J].Cancer,1996,78(10):2049-2062.
8Mutch DG.Surgery for recurrent epithelial ovarian cancer[J].Sem in Oncol,2002,29(suppl 1):3-8.
9Gadducci A,Iacconi P,Cosio S,et al.Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer[J].Gynecol Oncol,2000,79:344-349.
10Cantu MG,Buda A,Parma G,et al.Randomized contrailed trial of sing lengent paclitaxel versus cyclophosphamide,doxorubicin,and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens[J].J Clin Oncol,2002,20 (5):1232-1237.
